Bruker Launches Ultimate Sensitivity timsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics
Bruker has introduced the timsTOF Ultra 2, a highly sensitive system for advanced 4D-Proteomics, at the ASMS 2024 meeting. This system significantly enhances the ability to profile small cells and subcellular organelles, identifying and quantifying up to 50% more protein groups and 100% more peptides with very low sample amounts. The new Spectronaut 19 software further improves data analysis, enabling better protein quantitation. Bruker also launched the OmniScape software for top-down proteoform analysis and GlycoScape for real-time glycoproteomic data processing. The company has started shipping over 1,000 timsTOF systems, marking a significant milestone. Additionally, the new ENRICHplus kit from PreOmics offers a 7-fold improvement in plasma proteomics, highlighting the robustness of the timsTOF HT system.
- Bruker launches timsTOF Ultra 2 with up to 50% more protein groups and 100% more peptides identified.
- New Spectronaut 19 software improves data analysis and protein quantitation.
- Introduced OmniScape software for top-down proteoform analysis.
- GlycoScape software enables real-time glycoproteomic data processing.
- Launched ENRICHplus kit with 7-fold improvement in plasma proteomics.
- Shipment of over 1,000 timsTOF systems marks a significant milestone.
- No specific financial performance data provided in the press release.
- Potential high costs associated with the new technologies might limit accessibility for smaller research facilities.
Insights
The launch of Bruker's timsTOF Ultra 2 system represents a significant advancement in proteomics, the study of proteins within biological systems. The system's ability to detect over 1,000 proteins from as little as 25 picograms of sample material is a remarkable feat, allowing researchers to delve deeper into cellular and subcellular biology than ever before.
This level of sensitivity is particularly relevant in fields such as oncology and immunology, where identifying low-abundance proteins can lead to breakthroughs in understanding disease mechanisms and developing new treatments. The improved ion-charge control (ICC 2.0) method enhances the system's versatility, accommodating a broad range of sample sizes and ensuring consistent results across different experimental setups.
The integration of Biognosys' Spectronaut 19 software further enhances the system's capabilities. By leveraging advanced AI algorithms, SN19 improves the accuracy of protein quantification and identification, providing researchers with more reliable data. This is particularly important for large-scale studies where precision and reproducibility are paramount.
For retail investors, the continued innovation and integration of cutting-edge technology in Bruker's product lineup demonstrate the company's commitment to maintaining a leadership position in the proteomics market. This positions Bruker well for capturing a larger share of the growing proteomics market, estimated to reach
Bruker's launch of the timsTOF Ultra 2 and associated software packages underscores the company's strategic focus on high-end scientific instruments. The timsTOF Ultra 2's enhanced sensitivity and broader application range are likely to drive demand from academic and commercial research institutions. This could translate into significant revenue growth for Bruker, especially given the projected expansion of the proteomics market.
Furthermore, the successful shipment of over 1,000 timsTOF systems and the introduction of field upgrade options for existing users indicate strong customer adoption and satisfaction. This not only boosts recurring revenue through service contracts and software upgrades but also strengthens customer loyalty, reducing the likelihood of switching to competitors.
From a financial perspective, these innovations are likely to enhance Bruker's revenue streams and profit margins. The company’s investment in R&D, as reflected in these product launches, may result in short-term expense increases but should yield long-term benefits through market differentiation and competitive advantage.
The advancements in Bruker's timsTOF Ultra 2 system highlight significant improvements in proteomics research. The ability to identify and quantify more proteins and peptides with higher accuracy and sensitivity broadens the scope of biological and clinical research. This advancement is particularly beneficial for studies involving small sample sizes or low-abundance proteins, such as those in cancer research and personalized medicine.
The introduction of new software tools like OmniScape and GlycoScape further enhances the system's capabilities, offering researchers more comprehensive data analysis options. This integration of advanced software solutions positions Bruker as a leader in the proteomics field, providing a competitive edge over other market players.
Market trends indicate a growing demand for advanced proteomics tools, driven by the rising focus on personalized medicine and biomarker discovery. Bruker's innovative solutions are well-aligned with these trends, suggesting strong future market potential. For investors, Bruker's ability to stay ahead of technological advancements and meet market demands positions the company for sustained growth and profitability.
- timsTOF Ultra 2 enables significant further improvements in deep, high-fidelity 4D-Proteomics™ of mammalian cells, cancer cell lines, or tissue biopsies
- With sensitivity to measure >1000 proteins on just 25 pg, the timsTOF Ultra 2 opens new cell and disease biology research windows into PBMCs, small immune cells, bacterial cells, or subcellular organelle proteomics
-
timsTOF Ultra 2 enables identification and quantitation of ~
50% more protein groups and ~100% more peptides at 25 pg of digest sample with1% FDR -
timsTOF Ultra 2 typically yields ~
40% more peptides and ~20% more proteins for many other 4D-Proteomics applications with low-medium sample amounts - Improved ion-charge control (ICC 2.0) method makes timsTOF Ultra 2 suitable for a very broad range of sample loading, from low picograms to micrograms
- New OmniScape™ top-down proteoform software for automated, near-complete protein sequence coverage from MALDI-ISD and LC-TIMS-MS/MS data
- Biognosys launches Spectronaut® 19 (SN19) with optimized AI for further increased depth of protein quantitation and greater peptide sequence coverage
- SN19 now specifically trained on timsTOF MS/MS for significant 4D-Proteomics performance improvements; SN19 now fully integrated into timsTOF Ultra 2
- PreOmics launches reproducible and affordable deep plasma 4D-Proteomics ENRICHplus kit for 7-fold plasma depth improvement on robust timsTOF HT
- Novel capabilities for 4D-glycoprotein analysis: glyco-PASEF® and GlycoScape™
- Bruker announces customer shipment of more than 1,000 timsTOF systems
- Bruker launches 3 mass spectrometers at ASMS 2024 for 4D-Proteomics, mass-spec multiomics tissue imaging, and for highest-confidence applied analysis
The new timsTOF Ultra 2 delivers ultimate sensitivity (Photo: Business Wire)
Bruker Advances Ultimate Sensitivity with new timsTOF Ultra 2
The new timsTOF Ultra 2 delivers ultimate sensitivity of up to
New ion charge control (ICC2.0) software provides sample loading flexibility from low picogram amounts to about a microgram of protein digest.
Bruker ProteoScape™ software now integrates Spectronaut 19 (SN19) software from Biognosys, the gold-standard for data-independent analysis (DIA). The new SN19 offers significantly improved search engine AI, advanced quantification, and allows precise predictions of timsTOF’s unique collision cross sections (DeepCCS), retention time (DeepiRT) and fragment ion intensity (DeepFrag), resulting in a
Bruker once again intends to offer field upgrades to the timsTOF Ultra 2 for timsTOF Ultra/SCP customers.
PreOmics launches Reproducible, Affordable ENRICHplus Deep Plasma 4D-Proteomics Solution, Leveraging the Proven Robustness of the timsTOF HT
The new single particle PreOmics ENRICHplus kit and the timsTOF HT now deliver up to 7-fold improvement in protein identification and quantification versus neat plasma. The increased depth of coverage, together with field-proven throughput and robustness of the timsTOF HT enables deep plasma proteomics at scale. See PreOmics Press Release
Dr. Roman Fischer, Associate Professor and Head of Discovery, Proteomics Facility, University of
Bruker Launches OmniScape Top-Down Software for Analysis of Intact Proteins
Bruker is introducing OmniScape, the first top-down protein sequence software that covers protein de novo sequencing and lead sequence identification through homology searches for detailed proteoform analysis.
Dr. Boris Krichel, University of
OmniScape supports different data types from LC-CCS-MS/MS, enabling for example the analysis of multiply phosphorylated proteins. Its ability to integrate different datasets yields very high sequence coverages, providing reliable sequence calls and PTMs. OmniScape can also process MALDI-ISD top-down spectra from the timsTOF fleX and axial MALDI instruments including the new neofleX, as well as data from non-Bruker instruments as a one-for-all top-down protein sequencing and isoform determination software solution.
Dr. Christian Isak Jørgensen, Senior Science Manager, Novonesis,
Novel Acquisition and Computational Capabilities for 4D-Glycoproteomics
Bruker is introducing GlycoScape, the first real-time glycoproteomic software. GlycoScape has been developed in collaboration with the Radboud University Medical Center in the public-private partnership project EnFORCE led by Dr. Hans Wessels [1]. The software can identify glycopeptides on-the-fly as data are acquired and without the need to rely on glycan libraries, not only enabling identification of previously unreported glycans, but significantly minimizing false negative results. The unbiased read-out of glycoproteomic data by GlycoScape is critical for the advancement of glycobiology in translational and clinical research as these important research fields become accessible in the post-genomic era.
Dr. Hans Wessels, Senior Researcher at Radboud University in Nijmegen highlighted key advantages: “GlycoScape opens up the analysis of glycoproteomic mass spectrometry data from the timsTOF platform for on-the-fly processing without glycan database restrictions.”
GlycoScape leverages the glyco-PASEF method for ultra-sensitive and rapid glycoprotein data acquisition, using stepped energy CID and oxonium-ion-gated polygon-filtering, that was developed in collaboration with Prof. Albert Heck’s group at
Dr. Albert Heck, Professor of Chemistry and Pharmaceutical Sciences at
[1] The collaboration project is co-funded by PPP Allowance awarded by Health~Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships (Grant #LSHM21032).
About Bruker Corporation – the Emerging Leader of the Post-Genomic Era
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603348539/en/
Media
Petra Scheffer
Bruker Daltonics MarCom Manager
T: +49 (421) 2205-2843
E: Petra.Scheffer@bruker.com
Investor Relations
Justin Ward
Sr. Director Investor Relations & Corp Development
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Source: Bruker Corporation
FAQ
What is timsTOF Ultra 2?
How many protein groups can timsTOF Ultra 2 identify?
What new software accompanies timsTOF Ultra 2?
What is the significance of Spectronaut 19?
What is the ENRICHplus kit?
How many timsTOF systems has Bruker shipped?
